{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:18:37Z","timestamp":1792685917980,"version":"4.5.0"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T00:00:00Z","timestamp":1749686400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.msard.2025.106564","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T17:09:45Z","timestamp":1749661785000},"page":"106564","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Effectiveness of anti-CD20 therapies following natalizumab discontinuation: insights from a cohort study"],"prefix":"10.1016","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8525-2842","authenticated-orcid":false,"given":"Carolina","family":"Cunha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Matos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catarina","family":"Bernardes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00eas","family":"Carvalho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Campelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmo","family":"Mac\u00e1rio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00edvia","family":"Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f3nia","family":"Batista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00eas","family":"Correia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.msard.2025.106564_bib0001","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2217\/nmt-2021-0058","article-title":"Updates and advances in multiple sclerosis neurotherapeutics","volume":"13","author":"Amin","year":"2023","journal-title":"Neurodegener. Dis. Manag."},{"key":"10.1016\/j.msard.2025.106564_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103076","article-title":"How to switch disease-modifying treatments in multiple sclerosis: guidelines from the French Multiple Sclerosis Society (SFSEP)","volume":"53","author":"Bigaut","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2025.106564_bib0003","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1007\/s13311-021-01037-2","article-title":"Exit strategies in Natalizumab-treated RRMS at high risk of progressive multifocal leukoencephalopathy: a multicentre comparison study","volume":"18","author":"Zangh\u00ec","year":"2021","journal-title":"Neurotherapeutics"},{"issue":"7","key":"10.1016\/j.msard.2025.106564_bib0004","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/jamaneurol.2023.1542","article-title":"Comparison between Dimethyl fumarate, Fingolimod, and Ocrelizumab after Natalizumab cessation","volume":"80","author":"Zhu","year":"2023","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2025.106564_bib0005","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1086028","article-title":"Switch to ocrelizumab in MS patients treated with natalizumab in extended interval dosing at high risk of PML: a 96-week follow-up pilot study","volume":"14","author":"Santiago-Setien","year":"2023","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.msard.2025.106564_bib0006","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/ana.24651","article-title":"Rituximab versus fingolimod after natalizumab in multiple sclerosis patients","volume":"79","author":"Alping","year":"2016","journal-title":"Ann. Neurol."},{"issue":"8","key":"10.1016\/j.msard.2025.106564_bib0007","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1111\/ene.15406","article-title":"Confirmed disability progression as a marker of permanent disability in multiple sclerosis","volume":"29","author":"Sharmin","year":"2022","journal-title":"Eur. J. Neurol."},{"issue":"6","key":"10.1016\/j.msard.2025.106564_bib0008","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1007\/s00415-014-7325-8","article-title":"Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients","volume":"261","author":"Sorensen","year":"2014","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2025.106564_bib0009","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-40940-w","article-title":"Real-world evidence of ocrelizumab-treated relapsing multiple sclerosis cohort shows changes in progression independent of relapse activity mirroring phase 3 trials","volume":"13","author":"Ingwersen","year":"2023","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.msard.2025.106564_bib0010","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00415-025-12917-4","article-title":"Towards a biological view of multiple sclerosis from early subtle to clinical progression: an expert opinion","volume":"272","author":"Filippi","year":"2025","journal-title":"J. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2025.106564_bib0011","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40120-015-0038-9","article-title":"Natalizumab discontinuation and treatment strategies in patients with multiple sclerosis (MS): a retrospective study from two Italian MS centers","volume":"4","author":"Lo Re","year":"2015","journal-title":"Neurol. Ther."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825003062?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825003062?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:40:00Z","timestamp":1755650400000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825003062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":11,"alternative-id":["S2211034825003062"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106564","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of anti-CD20 therapies following natalizumab discontinuation: insights from a cohort study","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106564","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106564"}}